Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response

Addiction

Volumn 97, Issue 8, 2002, Pages 985-992

  Quaglio, Gianluca ^a   Talamini, Giorgio ^a   Lugoboni, Fabio ^a   Lechi, Alessandro ^a   Venturini, Luca ^a   Des Jarlais, Don C ^b   Mezzelani, Paolo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Drug users; Hepatitis B vaccination; Risk factors; Vaccine response

Indexed keywords

HEPATITIS VACCINE; RECOMBINANT VACCINE;

ADULT; AGE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEPATITIS B; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; ITALY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; SEROCONVERSION; SERODIAGNOSIS; TREATMENT INDICATION; VACCINATION;

ADULT; ANTIBODY FORMATION; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEROIN DEPENDENCE; HUMANS; ITALY; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME; VACCINATION;

EID: 0036342773     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-0443.2002.00147.x     Document Type: Article

References (42)

1. Hepatitis B in Wisconsin male prisoners: Considerations for serologic screening and vaccination
2. Hepatitis B vaccination in prisons: The Catalonian experience
3. Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination
4. Immunologic dysfunction in heroin addicts
5. Recommendations for protection against viral hepatitis
6. Immunization Practices Advisory Committee: Update on hepatitis B prevention
7. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or Pre S2 + S antigens
8. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination
9. Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination
10. Intravenous drug abusers and the acquired immunodeficiency syndrome (ADS). Demographic, drug use, and needle-sharing patterns
11. WHO strategy for the global elimination of new cases of hepatitis B
12. Global impact of hepatitis A virus infection: Changing patterns
13. Hepatitis B vaccination: How long does protection last?
14. Hepatitis B vaccination in patients with chronic hepatitis C
15. Vaccines to prevent viral hepatitis
16. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts
17. Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users
18. Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs
19. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen
20. Incidence of acute hepatitis B in injecting drug users as an indicator of continuing HIV transmission: International implications
21. Prevention of hepatitis B in Italy: Lessons from surveillance of type-specific acute viral hepatitis
22. Parallel decline in both HIV and HBV seroprevalence following AIDS prevention programmes among injecting drug users in North-East Italy
23. High compliance with a hepatitis B virus vaccination programme among intravenous drug users
24. Inhibition of cellular-mediated immunity in marihuana smokers
25. Hepatitis B vaccination. Information for patient is vital
26. Intravenous drug users: The only important reservoir of delta virus in Spain
27. Multicentre study of prevalence of HBV associated delta infection and liver disease in drug addicts
28. Immune response to hepatitis B vaccine in parenteral drug abusers
29. Low response rates to hepatitis B vaccine in former drug addicts
30. Suboptimal response to hepatitis B vaccine in drug users
31. Immune response to hepatitis B vaccine in drug addicts
32. Community-acquired opportunistic infections and defective cellular immunity in heterosexual drug abusers and homosexual men
33. Studio policentrico intersert sulla sieroprevalenza per l'HIVe l'HBV in 3637 tossicodipendenti dal 1986 al 1993
34. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C
35. Influence of smoking on immuno-logical responses to hepatitis B vaccine
36. Vaccination against hepatitis B: Comparison of three different vaccination schedules
37. + lymphocyte count and vaccination schedule
38. Risk factor for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers